LIPF
Gastric triacylglycerol lipase
As of the edition of 20 October 2026, LIPF (gastric triacylglycerol lipase, UniProt P07098) has 2 drugs tested at it and 6 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P07098
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 1
- Disease areas
- Nutrition and metabolism; Hormones; Cancer; Pregnancy and women's health; Urinary and reproductive; Heart and blood vessels; Inherited and neonatal; Digestive system
- Registered trials of its drugs
- 46
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Orlistat | Marketed | Phase 4 | none listed |
| Cetilistat | Marketed | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Undetermined | 5 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Cheplapharm Arzneimittel | Route B |
The other 5 companies at LIPF
In the product6 companies in all; 5 are not named here, and no score is.
See the 6 companies at LIPF, ranked, with the facts behind eachRequest access. Nothing is shown until you do.